Proposal for a Council Regulation (EC) amending Council Regulation (EC) No 297/95 on fees payable to the European Agency for the Evaluation of Medicinal Products. COM (98) 21 final, 21 January 1998 and VOM (98) 21 final/2, 8 April 1998 by unknown
• 
COMMISSION OF THE EUROPEAN COMMUNITIES 
Brussels, 21.01.1998 
COM(1998) 21  final 
LENDiiVG 
PROPOSAL FOR A COUNCIL REGULATION (EC) AMENDING COUNCIL 
REGULATION (EC) No 297/95 ON FEES PAY  ABLE TO THE EUROPEAN 
AGENCY FOR THE EVALUATION OF MEDICINAL PRODUCTS 
(presented by the Commission) l 
l 
---t- -----·  .- --·..  .  --- . ···--- ... --······ -- . 
COMMISSION OF THE EUROPEAN COMMUNITIES 
. CORruGHNDUM  \ 
·  au· documcmt COM(1998) 21  final 
du 21.01.1998. 
Amendement de la .Jere page 
du Reglement ainsi que 
I'  attribution d'un acronyme 
inter-insti tutionnel. 
(Conceme toutes les versions 
linguistiques.) 
• 
Brussels, 08.04.1998 
· COM(l998) 21  final/2 
98/0135 (CNS) 
. . 
PROPOSAL FOR A COUNCIL REGULATION (EC) AMENDING COUNCIL 
REGULATION (EC) No 297/95 ON FEES PAYABLE TO THE EUROPEAN 
AGENCY FOR THE EVALUATION OF MEDICINAL PRODUCTS 
(presented by the Commission) 
, 
.. 
.. 
• Explanatory memorandum 
Introduction: 
Pursuant to Council Regulation (EEC) No 2309/93 of22 July 1993
1 laying down Community 
procedures  for  the  authorisation  and  supervision  of medicinal  products  for  human  and 
veterinary use and establishing a European Agency for the Evaluation of Medicinal Products 
("'the  EMEA''),  the  Council  establishes  the  structure  and  the  amount  of fees  paid  by 
undertakings for  obtaining  and  maintaining  a Community  marketing  authorisation  and  for 
other services provided for by the EMEA. 
The current level and structure of fees  payable by the  pharmaceutical industry to the  EMEA 
was set out in Council  Regulation (EC) No 297/95
2 adopted on  I  0 February 1995. Artic'le  I 0 
of this Regulation provides that the Commission shall snbmit a report on  its implementation 
and,  in  the  light  of that  experience,  propose  a definitive  Regulation  to  the  Council.  The 
Council, acting by a qualified majority after consulting the  European Parliament. shall adopt 
provisions on the amounts of the fees and the conditions governing them, to apply as from  I 
January  1998. 
It was  acknowledged by Council  in  1995  that the  level of fees  provisionally adopted  was n 
temporary arrangement during the  transition  period ( 1995 to  1997). They were  not  intended 
to  fully  coyer  the  costs  associated  with  the  EMEA.  Fcc  revenue  is  complemented  by  a 
substantial contribution from  the  EU  general budget,  in  particular to cover the start-up costs 
for  the  Agency.  The structure of EMEA  fees  was deliberately kept simple and.  in  line  with 
orientations from  Council,  this was also to  be  re-examined along  with  the  fee  levels  in  the 
light of experience. 
In  preparing this proposal the Commission has sought to ensure to maintain the dual  aims of 
not  placing  an  undue  burden  on  applicants  and  not  endangering  the  achievement  of the 
EMEA's primary task of providing scientific advice of  the highest possible quality in relation 
to the authorisation and supervision of  medicinal products. 
The level of fees  proposed by the Commission are comparable to the levels put forward in  its 
initial  proposal for Council  Regulation (EC) No 297/95 (see COM(94)  167  final,  27.05.94). 
These figures were  later substantially reduced during the decision-taking procedure.  Despite 
EU  budgetary  difticulties,  it  is  expected . that  there  will  be  a  continuing  need  for  n 
contribution from  the Community,  in  particular to guarantee the  independence of the  EMEA 
with  regard to  the sector in which  it operates. This  independence will  be  further ensured by 
the  introduction  of an  annual  fee,  which  is  of a global  nature  and  will  therefore  balance 
revenue from fees for services received from individual companies. 
I  OJ L 214, 24.08.1993, p.l 
2 OJ L 35, I 5.02.1995, p.t 
1 Experience with the implementation of Regulation (EC) No 297/95: 
The  EMEA  was  invited  by  the  European  Commission  to  make  a  contribution  to  the 
preparation of this report based on its experience of the implementation of  the Regulation. 
A survey was carried out by the EMEA
3 on the costs of national competent authorities and 
the EMEA Secretariat associated with the operation of the centralised procedure. 
The basic findings endorsed by the EMEA Management Board are: 
•  The  current  fee  level  does  not  cover  the  real  costs  incurred  by  either  the 
national competent authorities or the Agency and would therefore  have to  be 
increased 
•  The  majority  of  EMEA  revenue  should  derive  from  fees,  "ith  a  certain 
proportion  of revenue  continuing to come  from  the  EU  budget:  this  would 
permit the EMEA to pursue EU policies of general interest 
•  The current fee  structure should be revised to introduce an  annual  fee  for  the 
funding  of  post-authorisation  maintenance  activities.  Given  the  resource 
implications of scientific advice, a specific fee  for that service should also be 
introduced 
•  A  range  of fees,  as  opposed to  fixed  fees,  might  be  introduced  ll' take  into 
account the complexity and workload related to certain types of  applications 
The results of the survey showed that the average cost for national competent authorities who 
had  acted as  rapporteur or co-rapporteur  in  the  evaluation of centralised  applications for 
medicines for human use was ECU 78 130. 
The  costs  of the  EMEA  Secretariat  were  calculated  at  ECU  188  710  per  application. 
Diff('rent  alternative analytical  accounting  methods  applied  sine~  th~  ~l'lllph:tit.'ll  L'f  tin: 
EMEA report have confirmed the magnitude of these costs. 
It appeared that the evaluation costs of veterinary medicinal products are similar to those of 
medicines for  human  use on  the  basis of the actual  workload required  t<>r  the applications. 
The EMEA l\lanagement Board therefore called for a convergence of fee lewis between both 
sectors for activities such as applications for marketing authorisations and arbitrations. 
Presentation of the proposal: 
The fee  le,·els proposed by  the Commission are designed to permit the El\IEA to continue to 
meet the  high scientific and organisational standards required by Council Regulation (EEC) 
No 2309/93. 
J  E  MEA report Contribl(t ion  lo tile preparation of  a Commis.'iion proposal  for a dejinil  ive 
Council Regulation on}i'es payable to the £'MEA,  EMEA/MB/057/96.Public 
2 As  a ·general  principle,  fees  for  obtaining  Community  marketing  authorisations  in  the 
centralised procedure should  be  comparable to  the  benefit derived  from  a single procedure 
and authorisation throughout the Community.  It  should therefore be more or less equivalent 
to but in  no case substantially higher than the total of  fees charged by the  IS Member States
4 
The basic full  fee for the evaluation of an  application for medicinal  products for human  LLse 
is proposed at ECU 200 000- the  same level as put forward by the Commission  in  its initial 
proposal for the current fee Regulation (COM(94) 167 final, 27.05.9.\). 
This  increase  in  fee  level  is  clearly demonstrated and  supported  by  the  cost survey of the 
national competent authorities and the EMEA. 
The Commission's proposal foresees three major new orientations. 
Firstly, the experience of the  EMEA  has  shown that certain variations of major  importance 
('type II  variations') do not  necessarily involve detailed scientific eval,pation.  It is  therefore 
proposed that the  possibility should be  introduced to permit the EI\IEA 1\lnnagemeitt Board, 
on  a proposal of the  Executive Director, to  determine those  cases  in  which  the  fee  payable 
for a type  II variation may be halved. 
The second initiative is  the introduction of an annual fee  which  is destined to meet the costs 
associated with the supervision and maintenance of medicinal products granted a Community 
marketing  authorisation.  These  activities  are  an  increasingly  important  part  of  the 
responsibilities  of all  regulatory  authorities.  They  also  draw  heavily  on  the  resources  of 
competent authorities since they are carried out continuously throughout the life of  a product. 
The introduction of an annual fee as proposed by the Commission is  in  line with the practices 
of many  national  competent  authorities.  According  to  information  suhmittcd  ll)  the  EMF/\ 
Se<:retariat,  annual  fees  arc  in  fact  levied  by· national  competent autlwrities  iu  II  of the  15 
Member States (all  Member States except Belgium, Germany, Austria and  Italy).  Levels of 
annual  fees vary considerably between national authorities, from  ECU  13  in  Luxembourg to 
a sales-based fee  potentially exceeding ECU  21  000  levied by the l'K \'eterinary Medicines 
Directorate.  As  the  EMEA  moves to  increasing reliance on  revenue  from  fees,  annual fees 
will  contribute to the  stability of financial  planning. A part of the annual  fee  will have to  be 
redistributed to Member States to cover the costs of market supervision undertaken on behalf 
of the Community. The rules for distribution among Member States "·ill  have  to  be adopted 
by the Agency's Management Board. 
Thirdly,  the  proposal  also  provides  for  the  introduction  of a  fee  for  scientitic  advice  and 
prot,,col assistance given to future applicants in the design of their research and development 
programmes.  The  experience  of the  EMEA  has  shown  that  this  service  can  demand 
con>iderable  scientific  and  resource  input.  From  the  perspective  of future  applicants,  the 
prcwision of  scientific advice on matters to which no alternative guidance  is  readily available 
can  be  of considerable  advantage  in  reducing  questions  raised  by  the  EMEA  during 
evaluation of an application for marketing authorisations. 
'Account should also be taken of the fact that under the EEA-Treaty, the scope of application of  a 
central marketing authorisation will possibly be extended to Norway, Iceland and- under specific 
circumstances- also to  Liechtenstein. New provisions also include initiatives for a  fee  for the establishment of maximum  residue 
limits  ('MRLs')  for  clinical  trials,  administrative  charges  and  the  introduction  of 
differentiated  fees  for  the  initiation  of Community  referral  procedures  under  Council 
Directives 75/319/EEC and 81/851/EEC. 
·In spite of the El'viEA's finding that the evaluation costs of veterinary medicinal products are 
similar to those of medicines for human use it was decided to take account of the specificity 
of the  market of veterinary  medicinal  products  and  the  public  and  animal  health  issues 
involved and to maintain the reduced fees for veterinary medicinal products 
In  accordance  with  Article  58  of Regulation  (EEC)  No  2309/93,  a  draft  of the  present 
proposal  was  forwarded  to  organisations  representing  the  interests  of the  pharmaceutical 
industry  at  Community  level.  The  Commission  carefully  examined  and  considered  all 
comments received before submitting the present proposal. 
The evolution of fees from  Council Regulation (EC) No 297/95 and  the current proposal is 
shown in the following comparative table: Fees for medicinal products for human use 
Council Regulation (EC)  Commission proposal 
No 297/95 
Full fee  ECU 140 000 to 200 000  ECU 200 000 
(add ECU 20 000 for additional  (add ECU 20 000 for additional 
strength and'or pharmaceutica_l  strength and/or pharmaceutical 
forms)  forms and ECU 5 000 for each 
additional  presen~1tion) 
Reduced fee  ECU 70 000 to  100 000  ECU 100 000 
(add ECU 10 000 for additional  (add ECU 20 000 for additional 
strength nnd.'or pharmaccutical  stnmgth and 'or  pharmac~.:ulic:11 
lorms)  flmns and  ECU 5 000 for each 
adllitinnJI  prcst:ntation) 
Extension fee  ECU 40 000  ECU 50 000 fl>r new strength, 
pharmaceutical form or indication 
ECU I  0 000 for new presentation 
of a strength and tom1 already 
authorised 
Type I variation  ECU 5 000  ECU 5 000 
Type II variation  ECU 40 000  ECU 60 000 
(possible reduction by half for 
specific type  II applications) 
Five year renewal fee  ECU 10 000  ECU  10 000 
Inspection fee  ECU  10 000  ECU 15 000 
Transfer of MA holder fee  ECU 5 000  ECU 5 000  -
Arbitration fee  ECU 30 000  ECU  10 000 where referral made 
by national authorities or 
Commission 
ECU 50 000 where referral made 
by applicant or MA holder 
Annual fee  nla  ECU 60 000 
Fer!  for scientific advice  nla  ECU 60 000 Fees for medicinal products for veterinary use
5 
Council Regulation (EC)  Commission proposal 
No 297/95 
Full fee  ECU 70 000 to  I  00 000  ECU  100 000 
(add ECU  I  0 000 for additional  (add  ECU  I  0 000 for additional 
str(:ngth and/or pharmaceutical  strength and/or pharmaceutical 
forms)  forms and ECU  5 000 for each 
additional presentation) 
Reduced fee  ECU 35 000 to 50 000  ECU 50 000 
(add ECU 5 000 for additional  (add ECU  I  0 000 for additional 
strength and'  or pharmaceutical  strength and:' or pharmaceutical 
forms)  forms and ECU 5 000 for each 
additional pr.:-scntatinn) 
Extension  fee  ECU 20 000  ECU  25 000 for new strength, 
pharmaceutical form  or indicatinn 
ECU 5 000 for new presentation 
of a strength and form  already 
authorised 
Type I variation  ECU 5 000  ECU 5 000 
Type II variation  ECU 20 000  ECU 30 000 
(possible n::duction by half for 
sp.:-citlc  typ.:- II  applic<Jtinns) 
Ma,imum residue limit (MRL)  ECU 40 000  ECU 50 000 
t~e 
Modification or extension of  an  ECU  10 000  ECll  I  0 00(1 
existing MRL 
MRL  for clinical trials  n/a  ECU  15000 
Five year renewal fee  ECU  5 000  ECU 5 000 
Inspection fee  ECU  10 000  ECU  15  000 
Transfer of MA  holder fee  ECU 5 000  ECU 5 000 
Arbitration fee  ECU  15000  ECU  10 000 \vhere  referral mad.: 
by national authoritit::s or 
Commission 
ECU 25 000 when.! n:ferral made 
by applicant or MA holdor 
Annual fee  n/a  ECU 30 000 
F.:~ fnr scientific ad vic~  n'a  ECU 30 000  - --·--
Th~  Commission proposal prov:dc·.;  foi- a reduction by h<::lf for applicatio;,s for marketing 
<1-uthorisations  for veterinary vacci;1e:'. (,.e.  fL<l!  f- ~ cf  .r:·.cu 50 000), rype  II  variations arc subjt:ct to 
a fee of ECU 5 000. I 
! 
"' 
.  '  . . . 
'  ' 
PROPOSAL FOR A COUNCIL REGULATION (EC) AMENDING COUNCIL 
REOULATION (EC) No 297/95 ON FEES PAYABLE TO THE EUROPEAN 
. AGENCY FOR THE. EVALUATION OF MEDICINAL PRODUCTS 
.  :THE. COUNCIL OF ~h-IE  EUROP~AN  UNION, 
'  . 
· Having. regard to the Treaty establisJting the  Eu.rope~n  C~mm~nity: 
Having  regard  to  ~ouncil Regulation  (EC)  No  297/95  of 10  February  1995  on  fees 
payable to the European Agency  for the Evaluation of Medicinal  Products I  (hereinafter 
referred to as 'the Agency'), and in particular Artick I  0 thereof, 
Having regard to the proposal from the Commission2, 
· ·  · ·.........,..  Having regard to the opinion of  the European Parliament3, 
;_, 
Whereas under Article 57(1) of Council Regulation No 2309/93  of 22 July  1993  laying 
down Community procedures for the authorisation and supervision of medicinal products 
for human and veterinary  u~e and establishing a European Agency for the Evaluation of 
Medicinal  Produ~s,4 the revenues of the  Agency consist of a contribution and  the  fees 
paid  by  undertakings  for  obtaining  and  maintaining  a  Community  marketing 
authorisation and for other services provided by the Agency; 
Whereas the amounts and structure of the fees established by RegulatiQn (EC) No 297/95  · 
must be reviewed before 31  December 1997; 
Whereas  in  view of the  experience gained  since  1995  it  is  appropriate  to  maintain the 
general  principles and  overall structure of the  fees  as  well  as  the  main operational and 
procedural provisions established by the abovementioned Regulation; 
Whereas tor certain fees, however, the services they relate to should be specified so as to 
facilitate their collection and  improve the  transparency and  practical  implementation of 
this Regulation;  , 
Whereas new fees must also be established to cover all the services now provided by the 
Agency; 
Whereas an annual fee must be introduced to ensure coverage of the costs connected with 
the  supervision of authorised  medicinal  products;  whereas a given  part of this  fee  will 
have  to go to the competent national authorities required under the  terms of Regulation 
(EEC)  No 2309/93  to  supervise  the  market  on  behalf of the  Community;  whereas, 
moreover, the rules for distribution among  those authorities will  have to  be adopted by 
the  Agency's Management  Board  in  accordance  with  the  procedure  laid  down  in  this 
. Regulation; 
I OJ L 35, 15.02.95, p.  I. 
2 
3  • 
4 OJ L 214, 24.~8.93, p.  I.  ..  .  \  •, 
'} 
.. 
.  .  . 
• Whereas,  in  certain  exceptional  cases  and  for  imperative  reasons  of public  or animal 
health, it must be possible to reduce the abovementioned fees; whereas, therefore, without 
prejudice to more specific provisions of  Community law,  any decision to reduce fees will 
have to be taken by the Executive Director on the basis of a critical  examination of the 
situation specific to each case after consultation of  the competent scientific committee, 
HAS ADOPTED THIS REGULATION: 
Article 1 
Regulation (EC) No 297/95 is hereby amended as follows: 
A 
l. Article l  i~ replaced by the following text: 
"Article l 
Fees for obtaining and maintaining a Community authorisation to market medicinal 
products for human and veterinary use and for the other services supplied by the 
Agency shall be levied in accordance with this Regulation. 
The amounts of  these fees shall be laid down in ecus." 
2. Articles 3 to II are replaced by the following text: 
"Article 3 
Medicinal  products for  human  use  covered by  the  procedures  laid  down  in  Council 
Regulation <EEC) No 2309/93 
(I)  Authorisation to market a medicinal product 
(a)  FuU fee 
The fee for an application for authorisation to market a medicinal product supported 
by a full  dossier is ECU 200 000.  It covers only one presentation of the medicinal 
product (for one strength associated with one pharmaceutical form). 
The  fee  shall  be  increased  by  ECU  20  000  for  each  additional  strength  and/or 
pharmaceutical  form  submitted  at  the  same  time  as  the  initial  application  for 
authorisation.  This increase covers only one presentation of the additional  strength 
and/or pharmaceutical form. 
The fee shall be increased by ECU 5 000 for each additional presentation of the same 
strength and pharmaceutical form, submitted at the same time as the initial application 
for authorisation. 
(b)  Reduced fee 
-s-
1 A reduced fee of  ECU 100 000 shall apply to applications for authorisation to market 
a medicinal product for which a full  dossier need not be presented, as provided for in 
Article 4  point 8(a)(i) and (iii) of Directive 65/65/EEC or when recourse is  had to 
Article 4 point 8 (a)(ii) of the same Directive. This fee  covers a single presentation 
(for one strength associated with one pharmaceutical form). 
The  fee  shall  be  increased  by  ECU 20 000  for  each  additional  strength  and/or 
pharmaceutical  form  submitted  at  the  same  time  as  the  initial  application  for 
authorisation.  This  increase covers only  one  presentation of the additional  strength 
and/or pharmaceutical form. 
The fee shall be increased by ECU 5 000 for each additional presentation of  the same 
strength and pharmaceutical form, submitted at the same time as the initial application 
for authorisation. 
(c) Extension fee 
This is the fee for each extension of a marketing authorisation which has already been 
granted: 
- where the extension is  for  a new strength,  a  new pharmaceutical  form  or a new 
indication, the fee is ECU 50 000; 
-where the extension is for a new presentation of a strength and  a pharmaceutical 
form which are already authorised, the fee is ECU I 0 000. 
(2)  Variation 
(a)  Type I variation fee 
J:he fee for a variation of minor importance to a marketing authorisation according to 
the classification established by the Commission Regulation applicable to the matter is 
ECU 5 000. 
(b)  Type II variation fee 
The fee for a variation of  major importance to a marketing authorisation according to 
the classification established by the Commission Regulation applicable to the matter is 
EC U 60 000.  It may  be  halved for  certain Type II variations which  do  not involve 
detailed scientific evaluation, a list of  which shall be drawn up in accordance with the 
procedure laid down in Article 11 (2) of  this Regulation. 
(3)  Renewal fee 
The fee for examining information available at the time of the five-yearly renewal of 
an  authorisation to market a medicinal  product is ECU 10 000.  It shall be charged 
for each strength associated with a pharmaceutical form. 
(  4)  Inspection fee 
-'3-The flat-rate fee for any inspection within or outside the Community is ECU 15 000. 
For inspections outside the Community, travel expenses will be charged extra on the 
basis of  actual cost. 
(  5)  Transfer fee 
The  fee  for  a  change  in  the  holder  of the  marketing  authorisations  to which  the 
transfer  relates  is  ECU 5 000.  This  covers  all  presentations  of a  given  medicinal 
product. 
(  6)  Annual fee 
The  annual  fee  for  each  medicinal  product  which  has  been  granted  a  marketing 
authorisation  is  ECU 60 000.  This  covers  all  authorised  presentations  of a  given 
medicinal product. 
Article 4 
Medicinal  products  for  human  use  covered  by  the  procedures  laid  down  m  CounJ;i.! 
Directive 75/319/EEC4 
An  arbitration  fee  of ECU I 0 000 shall  be payable where  the  procedures laid  down  in 
Articles 10(2),  11,  12 and  15 of  Directive 75/319/EEC are initiated. 
The fee shall be increased by ECU 40 000 where the procedures laid down in Articles II 
and  12  of Directive 75/319/EEC are initiated  at  the instigation of the  applicant  for  or 
holder of  the marketing authorisation. 
Article 5 
Medicinal products for  veterinary use covered by  the procedures laid  down  in  Council 
Regulation (EEC) No 2309/93 
(1)  Authorisation to market a medicinal product 
(a)  Full fee 
The fee for an application for authorisation to market a medicinal product supported 
by  a full  dossier  is  ECU 100 000. It covers only one presentation of the medicinal 
product (for one strength associated with one pharmaceutical form). 
The  fee  shall  be  increased  by  ECU I 0 000  for  each  additional  strength  and/or 
pharmaceutical  form  submitted  at  the  same  time  as  the  initial  application  for 
authorisation.  This  increase covers only one presentation of the additional  strength 
and/or pharmaceutical form. 
4 OJ L 147, 9.6.1975, p.  13.Dircctive last amended by Directive 93/39/EEC (OJ L 214, 24.8.1993, p. 22). 
lO The fee shall be increased by ECU 5 000 for each additional presentation of the same 
strength and pharmaceutical form, submitted at the same time as the initial application 
for authorisation. 
In the case of vaccines,  the full  fee  is reduced to ECU 50 000,  with each additional 
strength  and/or  pharmaceutical  form  and/or  presentation  entailing  an  increase  of 
ECU 5 000. 
For the purposes of  this paragraph, the number of  target species is irrelevant. 
(b)  Reduced fee 
A reduced fee ofECU 50 000 shall apply to applications for authorisation to market a 
medicinal product for which a full  dossier need not be presented, as provided for in 
Article 5 point IO(a)(i) and (iii) of  Directive 81/851/EEC or when recourse is had to 
Article 5 point  10  (a)(ii) of  the same Directive. This fee  covers a single presentation 
(for one strength associated with one pharmaceutical form of  the medicinal product). 
The  fee  shall  be  increased  by  ECU I  0 000  for  each  additional  strength  and/or 
pharmaceutical  form  submitted  at  the  same  time  as  the  initial  application  for 
authorisation.  This  increase covers only one presentation of the additional  strength 
and/or pharmaceutical form. 
The fee shall be increased by ECU 5 000 for each additional presentation of  the same 
strength and pharmaceutical form, submitted at the same time as the initial application 
for authorisation. 
In  the  case  of vaccines,  the  fee  is  reduced  to ECU 25 000,  with  each  additional 
strength  and/or  pharmaceutical  form  and/or  presentation  entailing  an  increase  of 
ECU 5 000. 
For the purposes of  this paragraph, the number of  target species is irrelevant. 
(c) Extension fee 
This is the fee for each extension of  a marketing authorisation which has already been 
granted: 
- where the extension is  for a new  strength,  a  new  pharmaceutical  form  or a  new 
species, the fee is ECU 25 000; 
- where the extension is  for a new  presentation of a strength and  a  pharmaceutical 
form which are already authorised, the fee is ECU 5 000; 
- in  the  case  of vaccines,  where  the  extension  is  for  a  new  strength,  a  new 
pharmaceutical form or a new presentation, the fee is ECU 5 000. 
(2)  Variation 
(a)  Type I variation fee 
II The fee for a variation of  minor importance to a marketing authorisation according to 
the classification established by the Commission Regulation applicable to the matter is 
ECU 5 000. The same fee is charged in respect of  vaccines. 
(b)  Type II variation fee 
The fee for a variation of  major importance to a marketing authorisation according to 
the classification established by the Commission Regulation applicable to the matter is 
ECU 30 000.  It may be halved for certain Type II variations which  do not involve 
detailed scientific evaluation, a list of  which shall be drawn up in accordance with the 
procedure laid down in Article 11 (2) of  this Regulation. 
In the case of  vaccines, the fee is ECU 5 000. 
(3)  Renewal fee 
The fee for examining available information at the time of the five-yearly  renewal of 
an authorisation to market a medicinal product is ECU 5 000.  It shall be charged for 
each strength associated with a pharmaceutical form. 
(  4)  Inspection fee 
The flat-rate fee for any inspection within or outside the Community is ECU 15 000. 
For inspections outside the Community, travel expenses will be charged extra on the 
basis of  actual cost. 
(5)  Transfer fee 
The fee  for  a  change  in  the  holder  of the  marketing  authorisations  to  which  the 
transfer  relates  is  ECU 5 000.  This  covers  all  presentations  of a  given  medicinal 
product. 
(6)  Annual fee 
The  annual  fee  for  each  medicinal  product  which  has  been  granted  a  marketing 
authorisation  is  ECU 30 000.  This  covers  all  authorised  presentations  of a  given 
medicinal product. 
Article 6 
Medicinal  products for  veterinary use covered by  the  procedures laid  down  in  Council 
Directive 81/851/EECS 
Arbitration fee 
An  arbitration  fee  of ECU I 0 000  shall  be payable  where the procedures laid  down in 
Articles 18(2),  19, 20 and 23 ofDirective 81/851/EEC are initiated. 
5 OJ L 147, 9.6.1975, p.  13. Directive last amended by Directive 93/39/EEC (OJ L 214, 24.8.1993, p.  22). The fee shall be increased by ECU 15 000 where the procedures laid down in Articles 19 
and 20 of Directive 81/851/EEC are initiated at the instigation of the applicant  for or 
holder of  the marketing authorisation. 
Article 7 
Establishment of  maximum residue limits (MRL) for veterinary medicinal products 
( 1)  Fees for establishing MRL 
A full  MRL fee of ECU 50 000  shall be charged for an application to set an  initial 
MRL for a given substance. 
An additional MRL fee ofECU 10 000 shall be payable for each application to amend 
or extend an existing MRL, including to cover new species. 
MRL fees  will  be  deducted from  the fee  payable  for  an  application  for  marketing 
authorisation or an application to extend a marketing authorisation for  the medicinal 
product  containing  the  substance  for  which  a  MRL  has  been  set  where  such 
applications are submitted by the same applicant. However, this deduction may total 
no more than one half of  the fee to which it applies. 
(2}  'Maximum residue limit for clinical trials' fee 
A fee ofECU 15 000 shall be charged for any application to set a MRL with a view 
to clinical trials. 
The fee will be deducted from the amount of  the full MRL fee laid down in point 1 of 
this Article. 
Article 8 
Various fees 
(1)  Fee for scientific advice 
This fee  shall  be charged  where  an  application  is  made for  scientific  or technical 
advice  concerning  a  medicinal  product  before  an  application  is  submitted  for 
authorisation to market it. 
-For medicinal products for human use the fee is set at ECU 60 000. 
-For medicinal products for veterinary use the fee is set at ECU 30 000. 
(2)  Fees for administrative charges 
Fees shall be payable for administrative charges when documents or certificates are 
issued outside the framework of services covered by another fee provided for in this 
Regulation or upon conclusion of  the administrative validation of a dossier resulting 
in rejection of the application for which the dossier was submitted. The unit amount 
of such fees  may not exceed ECU 5 000.  In accordance with Article 11(2}  of this 
Regulation,  a  classification  shall  be  established  and  specified  by  the  Management 
Board. Article 9 
Possible fee reductions 
Without  prejudice  to  more  specific  prov1s1ons  of  Community  law,  in  exceptional 
circumstances and for imperative reasons of  public or animal health, fee reductions may be 
granted  case  by  case  by  the  Executive  Director  after  consultation  of the  competent 
scientific  committee.  Any  decision  taken  in  applicaticm  of this  Article  shall  state  the 
reasons on which it is based. 
Article 10 
Due date and belated payment 
(I)  Fees shall be payable on the date of receipt of  the relevant application unless specific 
provisions stipulate otherwise. 
The arbitration fee  shall  be payable within 30 days following referral to the Agency; 
the  annual  fee  shall  be  payable  within  30  days  following  the  anniversary  of the 
notification of  the marketing authorisation decision. 
The inspection fee shall be payable at the latest within 30 days following the date on 
which the inspection was carried out. 
(2)  Where  any  fee  payable  under  this  Regulation  remains  unpaid  at  its  due  date,  and 
without prejudice to the Agency's capacity to institute legal proceedings conferred on 
it  by Article 59 of Council Regulation (EEC) No 2309/93, the Executive Director of 
the Agency may decide either not to provide the requested services or to suspend all 
the services and procedures under way until  the whole of the relevant  fee  has  been 
paid. 
(3)  Fees shall  be  paid  in  ecus or in  the national currency of one of the  Member States 
according  to  the  exchange  rates  in  force,  which  shall  be  fixed  daily  by  the 
Commission.  However,  monthly conversion rates based on  the earlier rates may be 
fixed according to a calculation established by the Agency's Management Board. 
Article II 
Implementing rules 
(I)  On a proposal from the Executive Director and following  a favourable  opinion from 
the Commission, the Agency's Management Board shall  fix  the  rules  for  repaying a 
part  of the  resources  deriving  from  the  annual  fees  to  the  competent  national 
authorities involved in Community market supervision. 
(2)  Without  prejudice ·to  the  provisions  of this  Regulation  or  of Regulation  (EEC) 
No 2309/93,  the  Agency's  Management  Board  may,  on  a  proposal  from  the 
Executive Director, specifY any other provision proving necessary for the application 
of this Regulation. 
• (3)  In the event of  disagreement as to the classification of  an application in one of the fee 
categories laid  down  in  this Regulation,  the Executive Director shall  give a  ruling 
after consultation of  the competent scientific committee. 
Article 12 
Amendment 
Any amendment to this Regulation shall be adopted by the Council acting by a qualified 
majority after consulting the European Parliament. 
However, amendments to the amounts of the fees established by this Regulation shall be 
adopted in  accordance with the procedure laid down in  Article 73  of Regulation (EEC) 
No 2309/93. 
Within five years of  the entry into force of  this Regulation, the Commission shall present a 
report on its implementation, after consultation of  the Agency's Management Board." 
Article 2 
Entrv into force 
This Regulation shall enter into force on  the day following its publication in  the official 
Journal of  the European Communities. 
This  Regulation  shall  be binding  in  its  entirety  and  directly  applicable  in  all  Member 
States. 
Done at Brussels, ......................... . FINANCIAL STATEMENT 
I.  TITLE OF OPERATION 
Proposal for a Council Regulation on fees payable to  the European Agency for  the Evaluation 
of Medicinal Products. 
2.  BUDGET HEADING INVOLVED 
European Community contribution 85-3 I 2 0 
EMEA own  budget (see, e.g.,  EMEA statement of revenue and expenditure for financial 
year 1997, OJ No L.79 of20 March 1997, page 31) 
3.  LEGAL BASIS 
Articles 57 and 58 of Council Regulation (EEC) No 2309/93 of22 July 1993. 
The presentation of this second Regulation is  provided for in  Article  10 of c,,uncil Regulation 
(EC)  No  297/95  of I 0  February  1995  on  fees  payable  to  the  European  Agency  for  the 
Evaluation of Medicinal Products. 
4.  DESCRIPTION OF OPERATION 
4.1  General objective 
Completion of the  internal  market in  the  pharmaceuticals sector (medicinal  products for 
human and veterinary use). 
Contribute  to  protection  and  promotion  of public  and  animal  health  and  consumer 
protection through: 
- a  European  system  for  the  centralised  evaluation  and  authorisation  of 
biotechnology-derived and other innovative medicinal products: 
limiting risks of veterinary medicine residues  in  food-producing animals; 
- .an  arbitration  mechanism  where  Member States are  unable  to  agree  on  the 
mutual recognition of  national marketing authorisations; and 
- a Europe-wide system for the surveillance of  safety of  medicines. 4.2  Specific objectives 
Council  Regulation  (EEC) No  2309/93 of 22  July  1993  lays down  (centralised) Community 
procedures  for  the  authorisation  and  supervision  of medicinal  products  for  human  and 
veterinary use  and  establishes a  European Agency for the  Evaluation of Medicinal  Products 
(""EMEA'").  Three Council  Directives (93/39/EEC, 93/40/EEC and 93/41/EEC) complete the 
system fqr the authorisation of medicinal products under the decentralised (mutual recognition) 
procedure. 
Article 57(1) of Council  Regulation 2309/93  provides that the  resources of the  EMEA shall 
consist of: 
a contribution from the Community, and 
fees paid by undertakings for obtaining and maintaining a Community marketing 
authorisation and for other services provided by the EMEA 
Council  Regulation (EC) No  297/95 was adopted to implement a structure and  level of fees 
payable to the EMEA. 
This  proposal  is  presented  in  accordance  with  Article  l 0  of that  Regulation  under  which 
Council,  in  consultation with  Parliament,  is  required  to  adopt further  proYisions  to  apply as 
from  I  January  1998  on  the  basis  of practical  experience  of the  impkmentution  of tlw 
Regulation. 
4.3  Period co\"ered and arrangements for renewal or extension 
The proposed Regulation has no fixed duration. 
The  proposal  provides  that  while  Council  determines  the  categories  of  fees  levied  on 
applicants,  the  actual  level  of fees  may  be  modified  by  means  of a  Standing Committee 
procedure as set out in Article 73 of  Council Regulation (EEC) No 2309/93. 
Any  other changes  to  the  Regulation  may only  be  made  by  Council  alia consultation  of 
European Parliament. 
Within  five  years  of  its  entry  into  force,  the  Commission  will  present  a  report  on  the 
implementation of  the Regulation. 
5.  CLASSIFICATION OF EXPENDITURE OR REVENUE 
The contribution from the general budget of the European Community is classified as: 
Non-compulsory expenditure 
Differentiated appropriations 
ReYenue  from  fees  and  other  administrative  charges  levied  on  applicants  and  holders  of 
Community marketing authorisations are own resources for the EMEA budget. 6.  TYPE OF EXPENDITURE OR REVENUE 
6.1  Revenue of the EMEA 
Partial contribution to the revenue of  the EMEA from the Community budget 
Income from fees generate own res\}urces for the EMEA budget 
The proportion of fees  in  the total EMEA budget is expected to rise to about 75  percent by the 
year  2000.  Taking  into  account  the  increase  in  activities  of the  EMEA,  the  Community 
contribution should stabilise, at about the 19971evel ofECU 14 million. 
6.2  Expenditure of the EMEA 
Staff costs: 
Title I of  the budget covers salary costs of EMEA personnel, together with costs of interim 
and  other  external  support  staff.  Other  staff-related  expenditure  (social  welfare,  staff 
missions, annual medical costs, recruitment costs, etc.) is also made under this title. 
13uilding and equipment costs: 
Title  II  relates to  expenditure for  the  building occupied by  the  El\IEA. costs associalctl 
with  the  rental  of  the  building,  equipment,  IT  networks  and  other  miscellaneous 
operational costs. The costs of external studies are also met from this title. 
Operational expenditure: 
Title Ill of the budget ·relates to the operational expenditure of the EMEA. This covers in 
particular the costs of meetings and payments made to  Member State national competent 
authorities for the provision of  rapporteur and inspection services. 
,~ 7.  FINANCIAL IMPACT 
7.1  Method of  calculating the total  cost of the action 
The cost of the action is  calculated on the basis of workload projections prepared on the basis 
of  consultation  w.ith  appropriate  industry  representative  organis.ations  and  directly  with 
undertakings  in  the  sector.  The  budgetary  needs  are  therefore  established  in  line  with  the 
operational resources required to meet this expected workload and the work programme of the 
EMEA. 
EMEA budgetary perspectives (ECU millions) 
1998  1999  2000  cOOl'  2002* 
EMEA budgetary needs  33.9  44  48  5~  56 
Projected fee revenue  19.6  29.6  33.6  3i.6  41.6 
l"vfiscellaneous revenue  0.3  0.4  0.4  0.4  0.4 
(bank, interest etc) 
Shortfall to be met by  14  14  14  p  14 
Community contribution 
Article  71  of Council  Regulation  (EEC)  No  2309/93  provides  that  the  Commission  will 
produce  a  report  for  the  year  2000  on  the  European  authorisation  system,  including  the 
operation of the  EMEA. This may lead to a revision of the scope of the centralised procedure 
and activities of  the EMEA. 
It is therefore difficult to provide a meaningful forecast of activities over the next 5 year period 
beyond the year 2000.  On  the basis of the current scope of the activities  of the  EMEA the 
contribution of  the Community is not likely to exceed present levels. 
Projected fee  revenue is  calculated on the  basis of fee  levels and  structure presented  in  this 
proposal using a model based on the practical experience of  the EMEA. 
Calculations only take  into  account the  normal  activities of the  EtvtEA  "ithin the  European 
\lnic>n.  The extension of EMEA activities, e:g. to countries of the European lconc1Jllic  Area <'I' 
the accession of new Member States,would require additional resources. 
7.2  Itemised breakdown of cost 
At the request of the Commission, a contribution to the preparation of the ne11  Regulation was 
made by the EMEA which  looked at the costs of Member States and EMEA Secretariat in  the 
operation  of  the  centralised  procedure.  The  report  surveyed  Member  State  competent 
authorities on the actual costs associated with the evaluation of medicinal  products for which 
'These projections are made on the basis that EMEA scope of  activities will not be changed they had  acted as  rapporteur or co-rapporteur, or for which their inspection departments had 
provided services. The survey also looked at the costs of the EMEA Secretariat. 
The report of the Board, included detailed analysis of: 
actual costs of rapporteur and co-rapporteurship relating to the  centralised evaluation  of 
individual human and veterinary medicines  . 
costs of inspections carried out under the centralised procedure 
costs for variations, post-marketing sun·eillance, etc. 
estimated EMEA secretariat costs 
breakdown  of the  expected  resource  contributions  from  the  Member  States  to  EMEA 
activities 
The  report was  adopted  by  the  Management  Board of the  EMEA  on  5  february  1997  and 
transmitted to the Commission. The report, after deletion of confidential information, was also 
circulated  to  appropriate  European  interested  parties  and  made  available  to  the  public 
(EMEA/MB/057/96.Public). 
The Management Board made a number of findings, including: 
fee  levels provided  for  in Council Regulation (EC) No 297/95 do not cover the real costs 
incurred by either the  national competent authorities or the  EMEA. and that therefore fee 
levels should be increased  ~ 
current fee structure should be revised to introduce an annual fee  for the  funding of post-
authorisation surveillance and maintenance activities 
the Board also recommended that by the year 2000 the majority of  E~  lEA revenue should 
derive  from  fees,  with  perhaps 25  percent of revenue  continuing to come  from  the  EU 
budget 
the  analysis of actual costs incurred  by national  competent authorities  revealed  that  the 
average  cost  of  evaluation  for  a  medicinal  product  for  human  use  was  alnwst 
ECU  80  000  - considerably higher than the  ECU 35  000 to 50  000  currently  payable t<' 
rapporteurs or co-rapporteurs 
The Board also highlighted: 
that  costs associated  with  evaluation-related services  provided  by  the  EMEA  should  be 
recovered from  fees levied on applicants and Community marketing aud10risation holders 
the  importance  of comp¢~sation paid  to  them  to  finance  their  involvement  in  EMEA 
activities 
7.l  Pro,·isioaal schedule of appropriations 
Not applicablt, since this is a Community contribution to the EMEA budget. 7.4  Community contribution under heading BS-3 1 2 0 "European Agency for the 
Evaluation of Medicinal Products" 
Since  this  is  an  autonomous  body  endowed  with  legal  personality "'.'d  possessing  its  own 
hudgl'!, the contribution  from  the  Community  budget is  entered under !leading BS-312.  The 
amount or this contribution is estimated on the basis of the costs referred to above and expected 
fcc revenue. 
The proposed new level and structure of fees aims at allowing the EMEA, in  the long-term, to 
derive 75  percent of its revenues from  fees, with the Community contribution falling to about 
25  percent or total budget. 
Although  representing  a  gradually  smaller  proportion  of total  EMEA  revenue,  there  is  a 
continuing  need  for  a.  Community  contribution  to  cover  the  necessary  public  health  and 
supervisory  runctions  not  carried  Out  in  the  interest  of  specific  companies  k.~. 
phannacovig,ilancc, technical harmonisation, etc.). 
I )uring  the  initial  trausilillll  period,  the  ( 'ol!llllllnily  contrihutilm  fl'JH"l'Sl'llkd  a  snhstanti;~l 
proportionnl'the tntal  I·:MEA  h111l~~t. 
The  projected  EMEA  hudg,ctm-y  perspectives  show  a  clear  trend  to  a  rcductinn  nf  tht• 
proportion  from  over one  half to  one  quarter of the  total  budget.  The proposl·d  R~..·gubtil'll 
provides  fi.1r  a  leVel  and  structure of fees  which  should  permit  this  trend  tlw  the  ( \Hmmmit~ 
contrihution to the current activities of  the EMEA to  he continued iu  the tilton:. 
ll.  FRAU!) I'RIWICNTION MICASUimS 
Council  Regulation (EEC) No 2309/93  provides  l(>r  specilic adoption  and  bud~dary control 
procedures.  Each  year  the  Management  Board,  composed of representatives or the  Member 
St;ltCS,  Corum ission and  Pari iament, arc responsible  for ndopt ill  f.!,  the dra n  hudgct ( ;\rt ir  le 5  .s ). 
Current budgetary  controlntcchanisms arc dcscrihcd  in  Article 57.  im:luding  the  appnintnH.:nt 
of a  financial  controller  by  the  Management  Board  nnd  review  or  El\tF.-\  rcn:-mJl'  :md 
expenditure accounts hy the Court of Audito'". 
It  should he noted that a draft Regulation is under preparation hy the Commission "hich '"'uld 
transfer  the  financial  control  function  for  the  EMEA  to  the  Financial  Controller  or the 
Ct,mmissillll. 
21 9.  ELEMENTS OF COST-EIIFECTIVENESS ANALYSIS 
9.1  Specific and quantifiable objectives 
The  provisions  of Council  Regulation  (EEC)  No  2309/93  setting  up  the  new  European 
. registration  system  seek  to  promote  the  free  movement  of  medicinal  products  in  the 
Community, while at  the  same time  providing better public health protection. In  particular, it 
has  been shown since the centralised procedure entered into force that the Regulation  permits 
rapid  access  for  ne\V  medicinal  products  to  the  single  market  and  has  ensured  greater 
harmonisation of  the conditions governing the placing on the market of medicinal products. 
A single  evaluation,  meeting the  highest  possible  scientific  standards,  is  carried  out  by  the 
EivlEA. working in partnership with the Member States. The EMEA opinion forms the basis for 
the  Commission  decision-taking  procedure  for  the  granting  of  Community  marketing 
authorisations. 
Consequently. these provisions come under three mqjor Comnmnity ~trak~ics: 
completion of  the internal market in  the pharmaceuticals sector 
industrial  policy to  promote the competitiveness of European  research  and  development-
based companies 
creation  of a  trans-European  communications  and  early  warning  net\York.  linking  the 
competent authorities, the EMEA and the Commission 
9.2  Grounds for operation 
The justificntions made for Council Regulation (EC) No 297/95 continue to apply, namely that 
the new European authorisation system: 
prevents  unnecessary duplication of scientific evaluation  for  produ..::JS  authl'lri:;-:-d  thJ\)ll~h 
the centralised procedure by reducing the number of  evaluations fwm  15  to  I 
reduces scope for conflicts between competent authorities through technical harmonisation 
accelerated evaluation permits pharmaceutical companies to  make  their products available 
more quickly, giving patients faster access to innovative medicines 
promotes the single market and free circulation of pharmaceuticals through  the placing on 
the market of medicinal products under the same conditions throughout the  EU 
F\ en  taking  into  account recent  increases  in  the  fees  of Member Stnte  competent authorities, 
the  k1 el  of fees  payable  to  the  EMEA  for  a Community marketing  authorisation  amount to 
ah,,ut  half the  total  corrcspondin~ fees  payable  to  each  of the  fifteen  national  competent 
autllllritics. 
The  k\ cl  of fees  proposed  do  1wt place  an  excessive  burden  on  the  economic  resources of 
undatakings in  the  sector.  Research and  development costs for a new molecule are  generally 
estimated at ECU 200 million. The fees payable to the EMEA represent a very small proportion 
,,f this total. 
Experience over the first  two years show that in  return for  fees  paid  to  the  EMEA,  applicants 
receive a service which is both rapid and effective. Thus allowing inno\'ativc new medicines to 
22 be placed on the market more quickly than before - benefiting both patients and the European 
research and development-based industry. This also permits authorisation holders to  begin to 
recover their costs earlier. 
The amount of fees  payable by applicants therefore appears modest and  reasonable compared 
to  fees  payable at national level. It also represents an efficient means of financing the work of 
the EMEA, reducing the bur<len on the general budget of the Community. 
9.3  Monitoring and evaluation of the operation 
The principal performance indicators will continue to be: 
actual  number of applications submitted by  companies  under  the  centralised  procedure, 
taking into account the choice left open to undertakings 
level  of post-marketing surveillance activity  for  centrally-authorised  medicinal  products 
and other Community referral procedures for nationally authorised products 
compliance with  300-day evaluation and decision-taking deadline hy  the  El'vlEA  and  the 
Commission; the speed of the new syslcm is a crucial factor for the l'tlr•'Pcan rc·scarch and 
dcvclnpment based industry 
Given the  systematic  usc of the  mutual  recognition  procedure  for  the  m~~jMity or conventional 
medicines  from  the  beginning  of 1998,  it  is  expected  that  there  will  be  an  increase  in  the 
number of arbitrations  referred  to  the  EMEA.  This  will  also  be  an  important  performance 
indicator for the European authorisation system. 
Evaluation: 
the  EMEA Management Board  adopts an  annual  report on the  acti,·ities of the  Agency 
which is forwarded to the Member States, Commission, Council and Parliament (Article 56 
of Council Regulation (EEC) No 2309/93) 
the Executive Director of the EMEA is responsible for ensuring that time limits laid down 
for the adoption of  opinions are respected (Article 55) 
at  the  initiative of the Executive Director, the Management Board has put  in  place ''joint 
industry-regulators panel to review performance of  the EMEA 
An  evaluation of the  implementation  of the  proposed  Regulation  will  be  presented  by  the 
Commission within five years of its entry intn force. 
The Commission  is  also  required  to  present a  report  on  the  overall  implementation  of the 
centralised and decentralised European registration systen1s within six years of the entry into 
force of  Council Regulation (EEC) No 2309/93 (Article 71 ). ISSN 0254-1475 
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